相似文献
1
Erratum to 'Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival': [ESMO Open Volume 7, Issue 2, April 2022, 100409].《转移性乳腺癌治疗的重大进展：拓展治疗选择即延长生存期》勘误：[《ESMO 开放》第 7 卷，第 2 期，2022 年 4 月，100409]
ESMO Open. 2022 Jun;7(3):100472. doi: 10.1016/j.esmoop.2022.100472. Epub 2022 Apr 7.
2
Erratum to 'Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis': [ESMO Open Volume 6, Issue 2, April 2021, 100088].《HER2 阳性乳腺癌患者的辅助内分泌治疗：系统评价与荟萃分析》勘误：[《ESMO 开放》第 6 卷，第 2 期，2021 年 4 月，100088]
ESMO Open. 2021 Jun;6(3):100158. doi: 10.1016/j.esmoop.2021.100158.
3
Erratum to 'Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients': [ESMO Open Volume 7, Issue 1, February 2022, 100393].《对“回复：哌柏西利与质子泵抑制剂之间的药物相互作用可能显著影响转移性乳腺癌患者的临床结局”的勘误》：[《ESMO 开放》第 7 卷，第 1 期，2022 年 2 月，100393]
ESMO Open. 2022 Apr;7(2):100460. doi: 10.1016/j.esmoop.2022.100460. Epub 2022 Mar 17.
4
Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406].《“评估2019冠状病毒病对意大利肺癌患者诊断治疗途径延误的影响（COVID-DELAY研究）：来自真实世界的更少病例和更高分期”的勘误》：[《欧洲肿瘤内科学会开放》第7卷，第2期，2022年4月，100406]
ESMO Open. 2022 Apr;7(2):100471. doi: 10.1016/j.esmoop.2022.100471. Epub 2022 Apr 1.
5
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].《艾日布林联合贝伐单抗作为一线紫杉醇和贝伐单抗治疗后进展的HER2阴性转移性乳腺癌的二线治疗：一项多中心、II期、单臂试验（GIM11-BERGI）》勘误：[《ESMO Open》第6卷，第2期，2021年4月，100054]
ESMO Open. 2021 Apr;6(2):100097. doi: 10.1016/j.esmoop.2021.100097.
6
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].《GATTO研究的勘误：一项Ib期研究，将抗TA-MUC1抗体Gatipotuzumab与抗EGFR抗体Tomuzotuximab联合用于难治性实体瘤患者》：[《ESMO Open》第7卷，第2期，2022年4月，100447]
ESMO Open. 2022 Aug;7(4):100549. doi: 10.1016/j.esmoop.2022.100549. Epub 2022 Jul 13.
7
ESMO 2021-my top three abstracts in breast cancer.欧洲肿瘤内科学会（ESMO）2021年——我选出的乳腺癌领域三大摘要。
Memo. 2022;15(2):111-113. doi: 10.1007/s12254-022-00810-z. Epub 2022 May 6.
8
Erratum to 'How we treat medulloblastoma in adults': [ESMO Open Volume 6, Issue 4, August 2021, 100173].《成人髓母细胞瘤的治疗方法》勘误：[《ESMO开放杂志》第6卷，第4期，2021年8月，100173]。
ESMO Open. 2021 Dec;6(6):100327. doi: 10.1016/j.esmoop.2021.100327. Epub 2021 Nov 12.
9
Erratum to 'Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome': [ESMO Open Volume 6, Issue 1, February 2021, 100005].《“COVID-19 之前及期间癌症患者血液学和生化参数的纵向特征揭示与预后相关的特征”勘误》：[《ESMO 开放》第 6 卷，第 1 期，2021 年 2 月，100005]
ESMO Open. 2021 Apr;6(2):100056. doi: 10.1016/j.esmoop.2021.100056. Epub 2021 Jan 28.
10
Erratum to 'How we treat primary central nervous system lymphoma': [ESMO Open Volume 6, Issue 4, August 2021, 100213].《“我们如何治疗原发性中枢神经系统淋巴瘤”的勘误》：[《ESMO开放》第6卷，第4期，2021年8月，100213]
ESMO Open. 2021 Dec;6(6):100326. doi: 10.1016/j.esmoop.2021.100326. Epub 2021 Nov 10.
引用本文的文献
1
Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regions.来自意大利南部各地区的专家小组关于转移性乳腺癌表型特征及患者路径优化的多学科讨论。
Sci Rep. 2025 May 8;15(1):16029. doi: 10.1038/s41598-025-97071-7.
2
Personalized treatment approach for HER2-positive metastatic breast cancer.针对人表皮生长因子受体 2（HER2）阳性转移性乳腺癌的个体化治疗方法。
Med Oncol. 2024 Sep 25;41(11):252. doi: 10.1007/s12032-024-02504-4.
3
Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.在接受细胞周期蛋白依赖性激酶4/6抑制剂治疗的晚期乳腺癌患者中利用微小RNA进行液体活检。
Oncol Lett. 2024 Feb 28;27(4):181. doi: 10.3892/ol.2024.14314. eCollection 2024 Apr.
Zotero 插件